Consensus on Interpretation of Clinical Reports for Next-Generation Sequencing of Tumors

With the development of new therapeutic drugs and the optimization of multidisciplinary comprehensive treatment models, traditional pathological typing and detection methods are no longer sufficient to meet clinical needs. Next generation sequencing （NGS） has become a commonly used detection method by Chinese oncologists. In order to further assist clinicians to understand the annotation and interpretation of variants related to clinical targets or driver genes, sort out the logic of NGS reports, and improve the capture of key information, The Oncology Expert Group on the Interpretation of NGS Clinical Reports performed careful analysis, discussion, and summary based on the latest progress in NGS testing at home and abroad, and added some examples of NGS report interpretation, as well as interpretation of homologous recombination deficiency （HRD） and minimal/molecular/measurable residual disease （MRD） related content according to the “Guidelines for the Interpretation of Next-Generation Sequencing Clinical Reports”, and formulated the “Consensus on Interpretation of Clinical Reports for Next-Generation Sequencing of Tumors” to help clinicians make the right clinical decisions.